Kazia Therapeutics Annual Report 2021

32 Kazia Therapeutics Limited 32 Annual Report 2021 SHARES UNDER OPTION Unissued ordinary shares of Kazia Therapeutics Limited under option at the date of this report are as follows. All options are unlisted and were issued under the Company’s Employee Share Option Plan. Grant date Expiry date Exercise Price Closing Balance 5 September 2016 5 September 2021 $1.630 50,000 31 October 2016 1 November 2021 $1.380 12,500 12 October 2016 17 October 2021 $1.560 62,000 21 November 2016 23 November 2021 $1.380 50,000 7 August 2017 7 August 2022 $0.670 87,000 5 February 2018 5 February 2023 $0.780 320,000 4 January 2019 4 January 2024 $0.493 37,500 13 November 2019 4 January 2024 $0.493 1,200,000 13 January 2020 13 January 2025 $0.881 200,000 9 November 2020 13 January 2025 $0.881 800,000 9 November 2020 9 November 2024 $1.132 1,200,000 4 January 2021 4 January 2025 $1.690 200,000 4,219,000 No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the company or of any other body corporate. SHARES ISSUED ON THE EXERCISE OF OPTIONS The following ordinary shares of Kazia Therapeutics Limited were issued during the year ended 30 June 2021 and up to the date of this report on the exercise of options granted: Date options granted Exercise price Number of shares issued 7 August 2017 $0.670 121,500 5 February 2018 $0.780 120,000 4 January 2019 $0.490 200,000 441,500 INDEMNITY AND INSURANCE OF OFFICERS The consolidated entity has not indemnified the Directors and Executives of the consolidated entity for costs incurred, in their capacity as a Director or Executive, for which they may be held personally liable, except where there is a lack of good faith. During the financial year, the consolidated entity paid a premium in respect of a contract to insure the Directors and Executives of the consolidated entity against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium. INDEMNITY AND INSURANCE OF AUDITOR The consolidated entity has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the consolidated entity or any related entity against a liability incurred by the auditor. During the financial year, the consolidated entity has not paid a premium in respect of a contract to insure the auditor of the consolidated entity or any related entity. PROCEEDINGS ON BEHALF OF THE COMPANY No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.